Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies

Hematol Oncol. 2022 Oct;40(4):491-504. doi: 10.1002/hon.2987. Epub 2022 Apr 15.

Abstract

Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.

Keywords: Myelofibrosis; chronic myeloid leukemia; clinical; systemic mastocytosis; thrombosis; translational.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Graft vs Host Disease*
  • Hematology*
  • Hematopoietic Stem Cells
  • Humans
  • Myeloproliferative Disorders* / drug therapy